Novartis intends to purchase bulk mRNA active ingredient from BioNTech and fill it into sterile vials for shipment back to BioNTech for distribution.
Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, according to the Swiss drugmaker.
Novartis intends to purchase bulk mRNA active ingredient from BioNTech and fill it into sterile vials for shipment back to BioNTech for distribution.
This new agreement builds on an earlier agreement for the fill and finish of more than 50 million doses at the Novartis Stein site in Switzerland in 2021.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…